InterCure Ltd.
INCRHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, InterCure Ltd. focuses on Drug Manufacturers - Specialty & Generic services and products. InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and. The $68.0M market capitalization puts INCR squarely in micro-cap range for its industry. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Market Cap
$68.0M
Beta
0.64
P/E (TTM)
—
P/E (Fwd)
-3.06
EPS (TTM)
$-0.94
EPS (Fwd)
$-1.48
ROE
-9.3%
ROA
-5.8%
Cash
—
Total Debt
—
Free CF
-$37.4M
52W Change
-38.4%
Annual Financials
Cash vs Debt
Where INCR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, INCR finished 5.11% below its 150-day moving average ($4.70) and 3.88% below its 200-day moving average ($4.64). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INCR overbought or oversold?
At the October 20, 2026 close, INCR's RSI(14) was 26.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Free cash flow is running at -$37.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -9.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $388.7M (2022) to $270.2M (2025), a 30% decline worth watching.
The relatively low beta of 0.64 suggests INCR is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for InterCure Ltd. and its sector.